Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation

Schizophrenia Research

Volumn 52, Issue 1-2, 2001, Pages 87-99

  Auer, Dorothee P ^a   Wilke, Marko ^a   Grabner, Andreas ^a   Heidenreich, Jens O ^a   Bronisch, Thomas ^a   Wetter, Thomas C ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Choline containing compounds; Magnetic resonance proton spectroscopy; Membrane hypothesis; N Acetylaspartate; Phospholipids; Schizophrenia; Thalamus; Tissue segmentation

Indexed keywords

AMISULPRIDE; BENPERIDOL; CHLORPROMAZINE; CHOLINE; CLOZAPINE; CREATINE; HALOPERIDOL; INOSITOL; MYELIN; N ACETYLASPARTIC ACID; OLANZAPINE; PERAZINE;

ADULT; ARTICLE; ATROPHY; CELL DENSITY; CELL VOLUME; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRADATION; FEMALE; GLIA; GRAY MATTER; HISTOLOGY; HUMAN; MALE; METABOLISM; METABOLITE; MORPHOLOGY; NERVE CELL; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; REDUCTION; SCHIZOPHRENIA; THALAMUS; WHITE MATTER;

ADULT; ASPARTIC ACID; ATROPHY; CHOLINE; CREATINE; DOMINANCE, CEREBRAL; ENERGY METABOLISM; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROGLIA; PARIETAL LOBE; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES; SCHIZOPHRENIA; SYNAPTIC MEMBRANES; THALAMUS;

EID: 0035476825     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00155-4     Document Type: Article

References (48)

1. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging
2. Multimodal image coregistration and partitioning- A unified framework
3. Reduced glutamate in anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study
4. Quantitative proton spectroscopy of canine brain: In vivo and in vitro correlations
5. Proton magnetic resonance spectroscopy in schizophrenia
6. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging
7. Regionally specific neuronal pathology in untreated patients with schizophrenia: A proton magnetic resonance spectroscopic imaging study
8. Synaptic degeneration in thalamus in schizophrenia
9. 31P MRS of the schizophrenic brain in vivo
10. PET and MRI of the thalamus in never-medicated patients with schizophrenia
11. 1H-Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates
12. Neurochemical alterations in asymptomatic abstinent cocaine users: A proton magnetic resonance spectroscopy study
13. Schizophrenia and the anteroventral thalamic nucleus: Selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons
14. Reversible decreases in N-acetylaspartate after acute brain injury
15. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia
16. Relative concentrations of proton MR visible neurochemicals in gray and white matter in human brain
17. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia
18. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia
19. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: Preliminary report
20. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients
21. Increased serum phospholipase A2 activity in schizophrenia: A replication study
22. The neuropathology of schizophrenia. A critical review of the data and their interpretation
23. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effects
24. Fatty acid levels in the brains of schizophrenic patients and normal controls
25. The membrane hypothesis of schizophrenia
26. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy
27. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia
28. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging
29. Sensory gating mechanisms of the thalamus
30. 1H NMR spectroscopy: N-acetylaspartate, creatine and choline
31. 1H MRS choline: Correlation with in vitro chemistry/histology
32. Alzheimer disease: Depiction of increased cerebral myo-inositol with proton MR spectroscopy
33. 31P NMR spectra in vivo
34. 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia
35. Human brain tumours: Assessment with in vivo proton MR spectroscopy
36. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics
37. Increased platelet membrane lysophosphatidylcholine in schizophrenia
38. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics
39. Estimation of metabolite concentrations from localized in vivo proton NMR spectra
40. Assessment of brain connectivity in schizophrenics and healthy subjects with diffusion tensor imaging
41. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics
42. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain
43. Inositol levels are decreased in postmortem brain of schizophrenic patients
44. N-Acetylaspartate in neuropsychiatric disorders
45. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types
46. 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics- A study including 50 patients and 36 controls
47. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls
48. Frontal, temporal and striatal proton relaxation times in schizophrenic patients and normal comparison subjects